Kezar Life Sciences, Inc. (KZR) earnings
KZR earnings moved a median of +1.27% by the close. Quarterly and annual KZR reports and results, each read against the price at its own news timestamp. Back to the KZR overview →
19 measured KZR earnings events.
Where these KZR earnings landedvs 16 measured KZR earnings reactions
| Middle 50% of KZR earnings reactions | -2.15% to +2.05% |
|---|---|
| Median reaction (to close) | +1.27% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 KZR earnings events with a measured close landed between -2.15% and +2.05%; 56% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Kezar Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | — | — | |
| Form 10-K/A Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | +0.55% | +0.96% | |
| Form 10-K Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | +0.14% | +2.06% | |
| Form 10-Q Kezar Life Sciences, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Kezar Life Sciences Reports Third Quarter 2025 Financial Results | Press release | +0.00% | — | |
| Form 10-Q Kezar Life Sciences, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +2.05% | |
| Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | +2.05% | |
| Form 10-Q Kezar Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -1.90% | |
| Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | -1.90% | |
| Form 10-K Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | -1.41% | -0.70% | |
| Form 10-Q Kezar Life Sciences, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +3.86% | |
| Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | +3.86% | |
| Form 10-Q Kezar Life Sciences, For: Jun 30 | SEC filing · Form 10-Q | +1.32% | +1.58% | |
| Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +1.32% | +1.58% | |
| Form 10-Q Kezar Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | +0.63% | -3.41% | |
| Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +0.63% | -3.41% | |
| Form 10-K Kezar Life Sciences, For: Dec 31 | SEC filing · Form 10-K | +2.65% | +4.50% | |
| Form 10-Q Kezar Life Sciences, For: Sep 30 | SEC filing · Form 10-Q | -4.58% | -2.89% | |
| Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -4.58% | -2.89% |
Keep exploring
More KZR: analyst actions → · SEC filings → · KZR overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Apollo Medical Holdings, Inc. (AMEH) | 192 | +0.16% | 55% |
| Citius Pharmaceuticals, Inc. (CTXR) | 192 | -1.42% | 30% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
| Arbutus Biopharma Corporation (ABUS) | 191 | +0.11% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.